Related content

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 3, 2014-04 ,pp. : 447-451

Bentham Science Publishers

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Sodium-Glucose Co-Transporter 2 Inhibition in Diabetes Treatment: Current Evidence and Future Perspectives

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3647-3656

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

By  

Medicinal Chemistry, Vol. 10, Iss. 3, 2014-05 ,pp. : 304-317

Bentham Science Publishers

Access to resources Recommend Favorite